BARBIERI, Elena

BARBIERI, Elena  

Mostra records
Risultati 1 - 20 di 35 (tempo di esecuzione: 0.026 secondi).
Titolo Data di pubblicazione Autore(i) File
35. PREDICTORS OF HER2 FISH POSITIVITY IN PRIMARY BREAST CANCER DIAGNOSIS SCORED 2+ WITH IHC: RESULTS OF A SINGLE INSTITUTION ANALYSIS 1-gen-2010 Barbieri, E.; Bettelli, S.; Piacentini, F.; Ficarra, G.; Conte, Pf.; Guarneri, V.
Achievements and unmet needs in the management of advanced ovarian cancer 1-gen-2010 Guarneri, Valentina; Piacentini, Federico; Barbieri, Elena; Conte, Pierfranco
ACHIEVEMENTS AND UNMET NEEDS IN THE MANAGEMENT OF EPITHELIAL OVARIAN CANCER 1-gen-2010 Conte, P.; Piacentini, F.; Barbieri, E.; Guarneri, V.
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 1-gen-2023 D'Onofrio, Raffaella; Omarini, Claudia; Toss, Angela; Sperduti, Isabella; Piacentini, Federico; Barbolini, Monica; Cortesi, Laura; Barbieri, Elena; Pettorelli, Elisa; Chiavelli, Chiara; Dominici, Massimo; Moscetti, Luca
Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer 1-gen-2010 Guarneri, Valentina; Barbieri, Elena; Dieci, Mv; Piacentini, Federico; Conte, Pierfranco
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework 1-gen-2021 Tenedini, E; Celestini, F; Iapicca, P; Marino, M; Castellano, S; Artuso, L; Biagiarelli, F; Cortesi, L; Toss, A; Barbieri, E; Roncucci, L; Pedroni, M; Manfredini, R; Luppi, M; Trenti, T; Tagliafico, E
Biomarkers predicting clinical benefit: fact or fiction? 1-gen-2011 Guarneri, Valentina; Barbieri, Elena; Conte, Pierfranco
Change in HER2 Status in HER2 Positive Operable Breast Cancer Patients Treated with Neoadjuvant Chemotherapy with or without Anti-HER2 Therapy: Analysis of Two Consecutive Cohorts 1-gen-2011 Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, G; Bettelli, Stefania Raffaella; Conte, Pierfranco; Guarneri, Valentina
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 1-gen-2019 Barbolini, M; Omarini, C; Viola, L; Isca, C; Marchi, I; Caggia, F; Barbieri, E; Toss, A; Cortesi, L; Dominici, M; Piacentini, F.
Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management 1-gen-2008 Guarneri, Valentina; Giovannelli, Simona; Ficarra, G; Bettelli, Stefania Raffaella; Maiorana, Antonino; Piacentini, Federico; Barbieri, Elena; Dieci, Maria Vittoria; D'Amico, Roberto; Jovic, Gordana; Conte, Pierfranco
COMPARISON OF HER-2 STATUS IN PRIMARY BREAST CANCER AND METASTATIC SITES: RESULTS FROM A SINGLE INSTITUTION ANALYSIS 1-gen-2008 Guarneri, V.; Giovannelli, S.; Ficarra, G.; Bettelli, S.; Piacentini, F.; Barbieri, E.; Dieci, Mv.; Jovic, G.; Conte, Pf.
Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single Institution analysis 1-gen-2012 Dieci, Maria Vittoria; Barbieri, Elena; Piacentini, Federico; Ficarra, G; Bettelli, Stefania Raffaella; Dominici, Massimo; Conte, Pierfranco; Guarneri, Valentina
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens. 1-gen-2009 Leitzel, K; Conte, Pierfranco; Guarneri, Valentina; Barbieri, Elena; Huang, W; Ali, Sm; Haddad, M; Sperinde, J; Lie, Y; Weidler, J; Bates, M; Lipton, A.
Double-blind, placebo-controlled, multicentric randomized phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal HER2-negative, hormone receptor-positive operable breast cancer 1-gen-2011 Conte, Pierfranco; Guarneri, Valentina; D. G., Generali; A., Bottini; L., Bazzola; Piacentini, Federico; F., Artioli; K., Cagossi; G., Bisagni; M., Bagnalasta; Tagliafico, Enrico; Barbieri, Elena; L., Cavanna; A., Ravaioli; D'Amico, Roberto; Vicini, Roberto; A., Frassoldati
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial 1-gen-2019 Omarini, C; Sperduti, I; Barbolini, M; Isca, C; Bocconi, Alessandro; Toss, A; Cortesi, L; Barbieri, E; Piacentini, F; Cascinu, S; Moscetti, L
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 1-gen-2010 Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, Guido; Conte, Pierfranco; Guarneri, Valentina
Ki67 as a Predictor of Response and Long Term Survival in Hormone Receptor Positive/HER2 Negative Breast Cancer Patients Treated with Preoperative Chemotherapy 1-gen-2010 Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, G; Conte, Pierfranco; Guarneri, Valentina
Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II-III Breast Cancer 1-gen-2011 Guarneri, Valentina; Pecchi, A; Piacentini, Federico; Barbieri, Elena; Dieci, Mv; Ficarra, G; Tazzioli, Giovanni; Frassoldati, A; Battista, R; Canossi, Barbara; Mauri, C; D'Amico, Roberto; Conte, Pierfranco; Torricelli, Pietro
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY 1-gen-2009 Guarneri, V.; Piacentini, F.; Barbieri, E.; Frassoldati, A.; Ficarra, G.; D’Amico, R.; Conte, Pf.
Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma 1-gen-2012 M., Maur; Tomasello, Chiara; A., Frassoldati; Mv, Dieci; Barbieri, Elena; Conte, Pierfranco